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Résumé en
anglais
The role of autologous stem cell transplantation (ASCT) in patients with marginal
zone lymphoma (MZL) is debatable. This study investigated the outcome and
prognostic factors affecting the outcome of patients undergoing ASCT for MZL.
Eligible patients had non-transformed nodal, extra-nodal (MALT) or splenic MZL
(SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and
were reported to the European Society for Blood and Marrow Transplantation,
Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries.
The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and
33 SMZL]. Median age at transplantation was 56 years. The median number of prior
therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive
disease. 89% received a chemotherapy-based high-dose regimen. There were no
significant differences in patient and transplant characteristics between the 3
histological subtypes except for a lower percentage of patients previously treated
with rituximab in the MALT sub-group and more transplants performed in recent
years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative
incidence of relapse/progression and non-relapse mortality were 38% and 9%,
respectively. Five-year event-free survival (EFS) and overall survival (OS) were 53%
and 73%, respectively. Five-year cumulative incidence of second malignancies was
6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS
and OS. In addition, patients with SMZL had a shorter OS than those with MALT.
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